Back to search

Article

Safety and efficacy of immune checkpoint inhibitors in nasopharyngeal carcinoma patients with chronic hepatitis B virus infection

2022-04-13

Abstract excerpt

<h4>Purpose: </h4> To explore the safety and efficacy of immune checkpoint inhibitors in nasopharyngeal carcinoma patients with chronic hepatitis B virus (HBV) infection. <h4>Methods: </h4> We conducted a retrospective study of nasopharyngeal carcinoma patients with HBV infection who received immune checkpoint inhibitors at our medical centre from 1 February 2017, to 30 November 2021. The primary endpoint was trea...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
43528941-b0af-57b6-bf4b-f54580f928d5
DOI
10.21203/rs.3.rs-1542689/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and efficacy of immune checkpoint inhibitors in nasopharyngeal carcinoma patients with chronic hepatitis B virus infectionDOI 10.21203/rs.3.rs-1542689/v1
Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challengesSemantic proximity
Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome expression could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti–programmed cell death 1 monotherapySemantic proximity
Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapySemantic proximity
Molecular biomarkers of response to sintilimab combined with lenvatinib for locally advanced hepatitis B virus-associated hepatocellular carcinomaSemantic proximity
Anti-HBV Therapy in Hepatocellular Carcinoma May Affect the Symptoms of SARS-CoV-2 InfectionSemantic proximity
Investigational drugs for nasopharyngeal carcinoma.Semantic proximity
Clinical characteristics and prognostic analysis of 95 cases of recurrent/metastatic nasopharyngeal carcinoma treated with immunotherapy: a single-center retrospective studySemantic proximity
Plasma Epstein-Barr virus DNA for the prediction of treatment response and disease progression in non-keratinizing differentiated nasopharyngeal carcinomaSemantic proximity
Novel Oncolytic Virus VG161 in Hepatocellular Carcinoma Patients Refractory to Standard Systemic TherapiesSemantic proximity
Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis BSemantic proximity
Risk of hepatitis B virus reactivation in B-cell malignancies treated with BTK inhibitorsSemantic proximity
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B InfectionSemantic proximity
Select a neighboring publication to make it the new centre.